General classes and functions of four-helix bundle cytokines

Advances in Protein Chemistry

Volumn 52, Issue , 1998, Pages 1-65

  Nicola, Nicos A ^a   Hilton, Douglas J ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; CYTOKINE RECEPTOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH HORMONE; HORMONE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 9; LEPTIN; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; PLACENTA LACTOGEN; PROLACTIN; STEM CELL FACTOR; THROMBOPOIETIN; TYROSINE KINASE RECEPTOR;

BINDING AFFINITY; BINDING SITE; HEMATOPOIESIS; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW;

EID: 0031738669     PISSN: 00653233     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0065-3233(08)60432-5     Document Type: Review

References (373)

1. Bazan, J. F. (1990). Haemopoietic receptors and helical cytokines. Immunol. Today 11, 350-354.
2. Bazan, J. F. (1991). Neuropoietic cytokines in the hematopoietic fold. Neuron 7, 197-208.
3. Nicola, N. A., ed. (1994). "Guidebook to Cytokines and Their Receptors." Oxford University Press, Oxford.
4. Hou, X. S., and Perrimon, N. (1997). The JAK-STAT pathway in Drosophila. Trends Genet. 13, 105-110.
5. Leutz, A., Damm, K., Sterneck, E., Kowenz, E., Ness, S., Frank, R., Gausepohl, H., Pan, Y. C., Smart, J., Hayman, M. and Graf, T. (1989). Molecular cloning of the chicken myelomonocytic growth factor (cMGF) reveals relationship to interleukin 6 and granulocyte colony stimulating factor. EMBO J. 8, 175-181.
6. Nicola, N. A., Metcalf, D., Johnson, G. R., and Burgess, A. W. (1979). Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors. Blood 54, 614-627.
7. Burgess, A. W., and Metcalf, D. (1980). Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. Int. J. Cancer 26, 647-654.
8. Nicola, N. A., Metcalf, D., Matsumoto, M., and Johnson, G. R. (1983). Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J. Biol. Chem. 258, 9017-9023.
9. Reidhaar-Olson, J. F., De Souza-Hart, J. A., and Selick, H. E. (1996). Identification of residues critical to the activity of human granulocyte colony-stimulating factor. Biochemistry 35, 9034-9041.
10. Metcalf, D., and Nicola, N. A. (1995). "The Hemopoietic Colony-Stimulating Factors: From Biology to Clinical Applications." Cambridge University Press, Cambridge, UK.
11. Vose, J. M., and Armitage, J. O. (1995). Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 13, 1023-1035.
12. Lieschke, G. J., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K. J., Basu, S., Zhan, Y. F., and Dunn, A. R. (1994). Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737-1746.
13. Miyake, T., Kung, C. K., and Goldwasser, E. (1977). Purification of human erythropoietin. J. Biol. Chem. 252, 5558-5564.
14. Lin, F. K., Suggs, S., Lin, C. H., Browne, J. K., Smalling, R., Egrie, J. C., Chen, K. K., Fox, G. M., Martin, F., Stabinsky, Z., Badrawi, S. M., Lai, P. H., and Goldwasser, E. (1985). Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. U.S.A. 82, 7580-7584.
15. Jacobs, K., Shoemaker, C., Rudersdorf, R., Neill, S. D., Kaufman, R. J., Mufson, A., Seehra, J., Jones, S. S., Hewick, R., Fritsch, E. F., Kawakita, M., Shimuzu, T., and Miyake, T. (1985). Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature (London) 313, 806-810.
16. Metcalf, D., Nicola, N. A., and Gough, N. M. (1995). Hormones and blood cell production. In "Endocrinology" (L. J. DeGroot, ed.), pp. 2943-2963. Saunders, Philadelphia.
17. Shanks, J. H., Hill, C. M., Lappin, T. R., and Maxwell, A. P. (1996). Localization of erythropoietin gene expression in proximal renal tubular cells detected by digoxigenin-labelled oligonucleotide probes. J. Pathol. 179, 283-287.
18. Eckardt, K. U. (1996). Erythropoietin production in liver and kidneys. Curr. Opin. Nephrol. Hyperten. 5, 28-34.
19. Gopfert, T., Gess, B., Eckardt, K. U., and Kurtz, A. (1996). Hypoxia signalling in the control of erythropoietin gene expression in rat hepatocytes. J. Cell. Physiol. 168, 354-361.
20. Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., Korbet, S., Krantz, S. B., Lundin, A. P., Nissenson, A. R., Ogden, D. A., Paganini, E. P., Rader, B., Rutsky, E. A., Stivelman, J., Stone, W. J., Teschan, P., Van Stone, J. C., Van Wyck, D. B., Zuckerman, K., and Adamson, J. W. (1989). Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992-1000.
21. Stephenson, J. R., Axelrad, A. A., McLeod, D. L., and Shreeve, M. M. (1971). Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc. Natl. Acad. Sci. U.S.A. 68, 1542-1546.
22. Broudy, V. C., Lin, N. L., and Kaushansky, K. (1995). Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85, 1719-1726.
23. 22a. Keleman, E., Cserhati, I., and Tanos, B. (1958). Demonstration and some properties of human thrombopoietin in thrombocythemic sera. Acta Haematol. 20, 350-353.
24. Methia, N., Louache, F., Vainchenker, W., and Wendling, F. (1993). Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 82, 1395-1401.
25. de Sauvage, F. J., Hass, P. E., Spencer, S. D., Malloy, B. E., Gurney, A. L., Spencer, S. A., Darbonne, W. C., Henzel, W. J., Wong, S. C., Kuang, W. J., Oles, K. J., Hultgren, B., Solberg, L. A., Goeddel, D. V., and Gaton, D. L. (1994). Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MpI ligand. Nature (London) 369, 533-538.
26. Bartley, T. D., Bogenberger, J., Hunt, P., Li, Y. S., Lu, H. S., Martin, F., Chang, M. S., Samal, B., Nichol, J. L., Swift, S., Johnson, M. J., Hsu, R.-Y., Parker, V. P., Suggs, S., Skrine, J. D., Merewether, L. A., Clogston, C., Hsu, E., Hokom, M. M., Hornkohl, A., Choi, E., Pangelinan, M., Sun, Y., Mar, V., McNinch, J., Simonet, L., Jacobsen, F., Xie, C., Shutter, J., Chute, H., Basu, R., Selander, L., Trollinger, D., Sieu, L., Padilla, D., Trail, G., Elliott, G., Izumi, R., Covey, T., Crouse, J., Garcia, A., Xu, W., Del Castillo, J., Biron, J., Cole, S., Hu, M. C.-T., Pacifici, R., Ponting, I., Saris, C., Wen, D., Yung, Y. P., Lin, H., and Bosselman, R. A. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. (Cambridge, Mass.) 77, 1117-1124.
27. Lok, S., Kaushansky, K., Holly, R. D., Kuijper, J. L., Lofton-Day, C. E., Oort, P. J., Grant, F. J., Heipel, M. D., Burkhead, S. K., Kramer, J. M., Bell, L. A., Sprecher, C. A., Blumberg, H., Johnson, R., Prunkard, D., Ching, A. F. T., Mathewes, S. L., Bailey, M. C., Forstrom, J. W., Buddle, M. M., Osborn, S. G., Evans, S. J., Sheppard, P. O., Presnell, S. R., O'Hara, P. J., Hagen, F. S., Roth, G. J., and Foster, D. C. (1994). Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature (London) 369, 565-568.
28. Foster, D., and Hunt, P. (1997). The biological significance of truncated and full-length forms of mpl ligand. In "Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical and Clinical Biology" D. J. Kuter, P. Hunt, W. Sheridan, and D. Zucker-Franklin, eds., pp. 203-214. Humana Press, Totowa, NJ.
29. Foster, D. C., Sprecher, C. A., Grant, F. J., Kramer, J. M., Kuijper, J. L., Holly, R. D., Whitmore, T. E., Heipel, M. D., Bell, L. A., Ching, A. F., McGrane, V., Hart, C., O'Hara, P., and Lok, S. (1994). Human thrombopoietin: Gene structure, cDNA sequence, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U.S.A. 91, 13023-13027.
30. Cohen-Solal, K., Villeval, J. L., Titeux, M., Lok, S., Vainchenker, W., and Wendling, F. (1996). Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 88, 2578-2584.
31. Fielder, P. J., Gurney, A. L., Stefanich, E., Marian, M., Moore, M. W., Carver-Moore, K., and de Sauvage, F. J. (1996). Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87, 2154-2161.
32. Stoffel, R., Wiestner, A., and Skoda, R. C. (1996). Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 87, 567-573.
33. Shivdasani, R. A., Rosenblatt, M. F., Zucker-Franklin, D., Jackson, C. W., Hunt, P., Saris, C. J., and Orkin, S. H. (1995). Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell (Cambridge, Mass.) 81, 695-704.
34. Emmons, R. V., Reid, D. M., Cohen, R. L., Meng, G., Young, N. S., Dunbar, C. E., and Shulman, N. R. (1996). Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87, 4068-4071.
35. Eaton, D. L., and de Sauvage, F. J. (1997). Thrombopoietin: The primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp. Hematol. 25, 1-7.
36. Harker, L. A., Toombs, C. F., and Stead, R. B. (1997). In vivo dose-response effects of Mpl ligands on platelet production and function. In "Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology" (D. J. Kuter, P. Hunt, W. Sheridan, and D. Zucker-Franklin, eds.), pp. 301-319. Humana Press, Totowa, NJ.
37. Gurney, A. L., Carver-Moore, K., de Sauvage, F. J., and Moore, M. W. (1994). Thrombocytopenia in c-mpl-deficient mice. Science 265, 1445-1447.
38. Carver-Moore, K., Broxmeyer, H. E., Luoh, S. M., Cooper, S., Peng, J., Burstein, S. A., Moore, M. W., and de Sauvage, F. J. (1996). Low levels of erythroid and myeloid progenitors in thrombopoietin-and-c-mpl-deficient mice. Blood 88, 803-808.
39. Alexander, W. S., Roberts, A. W., Nicola, N. A., Li, R., and Metcalf, D. (1996). Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87, 2162-2170.
40. de Vos, A. M., Ultsch, M., and Kossiakoff, A. A. (1992). Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 255, 306-312.
41. Daughaday, W. H. (1995). Growth hormone, insulin-like growth factors and acromegaly. In "Endocrinology" (L. J. DeGroot, ed.), pp. 303-329. Saunders, Philadelphia.
42. Cooke, N. E. (1995). Prolactin: Basic physiology. In "Endocrinology" (L. J. DeGroot, ed.), pp. 368-393. Saunders, Philadelphia.
43. Kooijman, R., Hooghe-Peters, E. L., and Hooghe, R. (1996). Prolactin, growth hormone, and insulin-like growth factor-I in the immune system. Adv. Immunol. 63, 377-454.
44. 42a. Kelley, K. W., Brief, S., Westly, H. J., Novakofski, J., Bechtel, P. J., Simon, J., and Walker, E. B. (1986). GH3 pituitary adenoma cells can reverse thymic aging in rats. Proc. Natl. Acad. Sci. USA 83, 5663-5667.
45. Ranke, M. B. (1995). Growth hormone insufficiency: Clinical features, diagnosis and therapy. In "Endocrinology" (L. J. DeGroot, ed.), pp. 330-340. Saunders, Philadelphia.
46. Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., and Friedman, J. M. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546.
47. Chen, H., Charlat, O., Tartaglia, L. A., Woolf, E. A., Weng, X., Ellis, S. J., Lakey, N. D., Culpepper, J., Moore, K. J., Breitbart, R. E., Duyk, G. M., Tepper, R. I., and Morgenstern, J. P. (1996). Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell (Cambridge, Mass.) 84, 491-495.
48. Gettys, T. W., Harkness, P. J., and Watson, P. M. (1996). The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rat adipocytes. Endocrinology (Baltimore) 137, 4054-4057.
49. Miller, S. G., De Vos, P., Guerre-Millo, M., Wong, K., Hermann, T., Staels, B., Briggs, M. R., and Auwerx, J. (1996). The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression. Proc. Natl. Acad. Sci. U.S.A. 93, 5507-5511.
50. Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., and Flier, J. S. (1996). Role of leptin in the neuroendocrine response to fasting. Nature (London) 382, 250-252.
51. Barash, I. A., Cheung, C. C., Weigle, D. S., Ren, H., Kabigting, E. B., Kuijper, J. L., Clifton, D. K., and Steiner, R. A. (1996). Leptin is a metabolic signal to the reproductive system. Endocrinology (Baltimore) 137, 3144-3147.
52. Gura, T. (1997). Obesity sheds its secrets. Science 275, 751-753.
53. Bennett, B. D., Solar, G. P., Yuan, J. Q., Mathias, J., Thomas, G. R., and Matthews, W. (1996). A role for leptin and its cognate receptor in hematopoiesis. Curr. Biol. 6, 1170-1180.
54. Gainsford, T., Wilson, T. A., Metcalf, D., Handman, E., McFarlane, C., Ng, A., Nicola, N. A., Alexander, W. S., and Hilton, D. J. (1996). Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. U.S.A. 93, 14564-14568.
55. Cioffi, J. A., Shafer, A. W., Zupancic, T. J., Smith-Gbur, J., Mikhail, A., Platika, D., and Snodgrass, H. R. (1996). Novel B219/OB receptor isoforms: Possible role of leptin in hematopoiesis and reproduction. Nat. Med. 2, 585-589.
56. Mandel, M. A., and Mahmoud, A. A. (1978). Impairment of cell-mediated immunity in mutation diabetic mice (db/db). J. Immunol. 120, 1375-1377.
57. Stanley, E. R., Berg, K. L., Einstein, D. B., Lee, P. S., and Yeung, Y. G. (1994). The biology and action of colony stimulating factor-1. Stem Cells 1, 15-24.
58. Williams, D. E., de Vries, P., Namen, A. E., Widmer, M. B., and Lyman, S. D. (1992). The Steel factor. Dev. Biol. 151, 368-376.
59. Lyman, S. D., Brasel, K., Rousseau, A. M., and Williams, D. E. (1994). The flt3 ligand: A hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells 1, 99-107.
60. Lyman, S. D. (1995). Biology of flt3 ligand and receptor. Int. J. Hematol. 62, 63-73.
61. Manova, K., Huang, E. J., Angeles, M., De Leon, V., Sanchez, S., Pronovost, S. M., Besmer, P., and Bachvarova, R. F. (1993). The expression pattern of the c-kit ligand in gonads of mice supports a role for the c-kit receptor in oocyte growth and in proliferation of spermatogonia. Dev. Biol. 157, 85-99.
62. Keshet, E., Lyman, S. D., Williams, D. E., Anderson, D. M., Jenkins, N. A., Copeland, N. G., and Parada, L. F. (1991). Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development. EMBO J. 10, 2425-2435.
63. Hannum, C., Culpepper, J., Campbell, D., McClanahan, T., Zurawski, S., Bazan, J. F., Kastelein, R., Hudak, S., Wagner, J., Mattson, J., Luh, J., Duda, G., Martina, N., Peterson, D., Menon, S., Shanafelt, A., Muench, M., Kelner, G., Namikawa, R., Rennick, D., Roncarolo, M.-G., Zlotnik, A., Rosnet, O., Dubreuil, P., Birnbaum, D., and Lee, F. (1994). Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature (London) 368, 643-648.
64. Guilbert, L., Robertson, S. A., and Wegmann, T. G. (1993). The trophoblast as an integral component of a macrophage-cytokine network. Immunol. Cell Biol. 71, 49-57.
65. Williams, D. E., Fletcher, F. A., Lyman, S. D., and de Vries, P. (1991). Cytokine regulation of hematopoietic stem cells. Semin. Immunol. 3, 391-396.
66. Broxmeyer, H. E., Maze, R., Miyazawa, K., Carow, C., Hendrie, P. C., Cooper, S., Hangoc, G., Vadhan-Raj, S., and Lu, L. (1991). The kit receptor and its ligand, steel factor, as regulators of hemopoiesis. Cancer Cells 3, 480-487.
67. Namikawa, R., Muench, M. O., and Roncarolo, M. G. (1996). Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells 14, 388-395.
68. Brashem-Stein, C., Flowers, D. A., and Bernstein, I. D. (1996). Regulation of colony-forming cell generation by flt-3 ligand. Br. J. Haematol. 94, 17-22.
69. Hjertson, M., Sundstrom, C., Lyman, S. D., Nilsson, K., and Nilsson, G. (1996). Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. Exp. Hematol. 24, 748-754.
70. Namikawa, R., Muench, M. O., de Vries, J. E., and Roncarolo, M. G. (1996). The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood 87, 1881-1890.
71. Hunte, B. E., Hudak, S., Campbell, D., Xu., Y., and Rennick, D. (1996). flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J. Immunol. 156, 489-496.
72. Hudak, S., Hunte, B., Culpepper, J., Menon, S., Hannum, C., Thompson-Snipes, L., and Rennick, D. (1995). FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood 85, 2747-2755.
73. Muench, M. O., Roncarolo, M. G., Menon, S., Xu, Y., Kastelein, R., Zurawski, S., Hannum, C. H., Culpepper, J., Lee, F., and Namikawa, R. (1995). FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 85, 963-972.
74. Hirayama, F., and Ogawa, M. (1996). Cytokine regulation of early lymphohematopoietic development. Stem. Cells 14, 369-375.
75. Costa, J. J., Demetri, G. D., Harrist, T. J., Dvorak, A. M., Hayes, D. F., Merica, E. A., Menchaca, D. M., Gringeri, A. J., Schwartz, L. B., and Galli, S. J. (1996). Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J. Exp. Med. 183, 2681-2686.
76. Langtimm-Sedlak, C. J., Schroeder, B., Saskowski, J. L., Carnahan, J. F., and Sieber-Blum, M. (1996). Multiple actions of stem cell factor in neural crest cell differentiation in vitro. Dev. Biol. 174, 345-359.
77. Packer, A. I., Besmer, P., and Bachvarova, R. F. (1995). Kit ligand mediates survival of type A spermatogonia and dividing spermatocytes in postnatal mouse testes. Mol. Reprod. Dev. 42, 303-310.
78. Wehrle-Haller, B., and Weston, J. A. (1995). Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development (Cambridge, UK) 121, 731-742.
79. De Felici, M., and Pesce, M. (1994). Growth factors in mouse primordial germ cell migration and proliferation. Prog. Growth Factor Res. 5, 135-143.
80. Besmer, P., Manora, K., Duttlinger, R., Huang, E. J., Packer, A., Gyssler, C., and Bachvarova, R. F. (1993). The kit-ligand (steel factor) and its receptor c-kit/W: Pleiotropic roles in gametogenesis and melanogenesis. Development (Cambridge, UK) Suppl. pp. 125-137.
81. Fleischman, R. A. (1993). From white spots to stem cells: The role of the Kit receptor in mammalian development. Trends Genet. 9, 285-290.
82. Hume, D. A., Pavli, P., Donahue, R. E., and Fidler, I. J. (1988). The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo. J. Immunol. 141, 3405-3409.
83. Williams, D. E., Hangoc, G., Cooper, S., Boswell, H. S., Shadduck, R. K., Gillis, S., Waheed, A., Urdal, D., and Broxmeyer, H. E. (1987). The effects of purified recombinant murine interleukin-3 and/or purified natural murine CSF-1 in vivo on the proliferation of murine high-and low-proliferative potential colony-forming cells: demonstration of in vivo synergism. Blood 70, 401-403.
84. Broxmeyer, H. E., Williams, D. E., Cooper, S., Hangoc, G., and Ralph, P. (1988). Recombinant human granulocyte-colony stimulating factor and recombinant human macrophage-colony stimulating factor synergize in vivo to enhance proliferation of granulocyte-macrophage, erythroid, and multipotential progenitor cells in mice. J. Cell. Biochem. 38, 127-136.
85. Cenci, E., Bartocci, A., Puccetti, P., Mocci, S., Stanley, E. R., and Bistoni, F. (1991). Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration. Infect. Immun. 59, 868-872.
86. Hiraoka, Y., Kishimoto, C., Takada, H., Suzaki, N., and Shiraki, K. (1995). Colony-stimulating factors and coxackievirus B3 myocarditis in mice: Macrophage colony-stimulating factor suppresses acute myocarditis with increasing interferon-alpha. Am. Heart J. 130, 1259-1264.
87. Nassar, F., Brummer, E., and Stevens, D. A. (1994). Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans. Antimicrob. Agents Chemother. 38, 2162-2164.
88. Neumanitis, J., Shannon-Dorcy, K., Appelbaum, F. R., Meyers, J., Owens, A., Day, R., Ando, D., O'Neill, C., Buckner, D., and Singer, J. (1993). Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 82, 1422-1427.
89. Sanda, M. G., Bolton, E., Mule, J. J., and Rosenberg, S. A. (1992). In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. J. Immunother. 12, 132-137.
90. Redman, B. G., Flaherty, L., Chou, T. H., Kraut, M., Martino, S., Simon, M., Valdivieso, M., and Groves, E. (1992). Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. J. Immunother. 12, 50-54.
91. Hume, D. A., Donahue, R. E., and Fidler, I. J. (1989). The therapeutic effect of human recombinant macrophage colony stimulating factor (CSF-1) in experimental murine metastatic melanoma. Lymphokine Res. 8, 69-77.
92. Medlock, E. S., Migita, R. T., Trebasky, L. D., Housman, J. M., Elliott, G. S., Hendren, R. W., Deprince, R. B., and Greiner, D. L. (1992). Rat stem-cell factor induces splenocytes capable of regenerating the thymus. Dev. Immunol. 3, 35-44.
93. Okada, S., Nakauchi, H., Nagayoshi, K., Nishikawa, S., Miura, Y., and Suda, T. (1992). In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood 80, 3044-3050.
94. Zsebo, K. M., Smith, K. A., Hartley, C. A., Greenblatt, M., Cooke, K., Rich, W., and McNiece, I. K. (1992). Radioprotection of mice by recombinant rat stem cell factor. Proc. Natl. Acad. Sci. U.S.A. 89, 9464-9468.
95. Hunt, P., Zsebo, K. M., Hokom, M. M., Hornkohl, A., Birkett, N. C., del Castillo, J. C., and Martin, F. (1992). Evidence that stem cell factor is involved in the rebound thrombocytosis that follows 5-fluorouracil treatment. Blood 80, 904-911.
96. Ulich, T. R., del Castillo, J., McNiece, I. K., Yi, E. S., Alzona, C. P., Yin, S. M., and Zsebo, K. M. (1991). Stem cell factor in combination with granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF synergistically increases granulopoiesis in vivo. Blood 78, 1954-1962.
97. Molineux, G., Migdalska, A., Szmitkowski, M., Zsebo, K., and Dexter, T. M. (1991). The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulaung factor. Blood 78, 961-966.
98. Ulich, T. R., del Castillo, J., Yi, E. S., Yin, S., McNiece, I., Yung, Y. P., and Zsebo, K. M. (1991). Hematologic effects of stem cell factor in vivo and in vitro in rodents. Blood 78, 645-650.
99. Andrews, R. G., Knitter, G. H., Bartelmez, S. H., Langley, K. E., Farrar, D., Hendren, R. W., Appelbaum, F. R., Bernstein, I. D., and Zsebo, K. M. (1991). Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. Blood 78, 1975-1980.
100. Hunt, P., and Foote, M. (1995). The new generation of recombinant human hematopoietic cytokines. Curr. Opin. Biotechnol. 6, 692-697.
101. Morstyn, G., Glaspy, J., Shpall, E. J., LeMaistre, F., Briddell, R., Menchaca, D., Lill, M., Jones, R. B., Tami, J., Brown, S., Yan, X.-Q., and McNiece, I. (1994). Clinical applications of filgrastim and stem cell factor in vivo and in vitro. J. Hematother. 3, 353-355.
102. Simmons, P. J., Leavesley, D. I., Levesque, J. P., Swart, B. W., Haylock, D. N., To, L. B., Ashman, L. K., and Juttner, C. A. (1994). The mobilization of primitive hemopoietic progenitors into the peripheral blood. Stem Cells 1, 187-201.
103. Hoffman, R., Tong, J., Brandt, J., Traycoff, C., Bruno, E., McGuire, B. W., Gordon, M. S., McNiece, I., and Srour, E. F. (1993). The in vitro and in vivo effects of stem cell factor on human hematopoiesis. Stem Cells 2, 76-82.
104. Lacerna, L. J., Basser, R., Begley, C. G., Crawford, J., Demetri, G. D., Moskowitz, C. H., Tricot, G., Weaver, A., Sheridan, W. P., and Glaspy, J. Stem cell factor. In "Hematopoietic Stem Cell Therapy" (R. E. Champlin and A. D. Ho, eds.) Cambridge University Press, Cambridge, U.K., in press.
105. Brasel, K., McKenna, H. J., Morrissey, P. J., Charrier, K., Morris, A. E., Lee, C. C., Williams, D. E., and Lyman, S. D. (1996). Hematologic effects of flt3 ligand in vivo in mice. Blood 88, 2004-2012.
106. Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., and McKenna, H. J. (1996). Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953-1962.
107. Michaelson, M. D., Bieri, P. L., Mehler, M. F., Xu, H., Arezzo, J. C., Pollard, J. W., and Kessler, J. A. (1996). CSF-1 deficiency in mice results in abnormal brain development. Development (Cambridge, UK) 122, 2661-2672.
108. Nilsson, S. K., and Bertoncello, I. (1994). The development and establishment of hemopoiesis in fetal and newborn osteopetrotic (op/op) mice. Dev. Biol. 164, 456-462.
109. Nilsson, S. K., and Bertoncello, I. (1994). Age-related changes in extramedullary hematopoiesis in the spleen of normal and perturbed osteopetrotic (op/op) mice. Exp. Hematol. 22, 377-383.
110. Begg, S. K., Radley, J. M., Pollard, J. W., Chisholm, O. T., Stanley, E. R., and Bertoncello, I. (1993). Delayed hematopoietic development in osteopetrotic (op/op) mice. J. Exp. Med. 177, 237-242.
111. Wiktor-Jedrzejczak, W., Ratajczak, M. Z., Ptasznik, A., Sell, K. W., Ahmed-Ansari, A., and Ostertag, W. (1992). CSF-1 deficiency in the op/op mouse has differential effects on macrophage populations and differentiation stages. Exp. Hematol. 20, 1004-1010.
112. Wiktor-Jedrzejczak, W., Urbanowska, E., Aukerman, S. L., Pollard, J. W., Stanley, E. R., Ralph, P., Ansari, A. A., Sell, K. W., and Szperl, M. (1991). Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp. Hematol. 19, 1049-1054.
113. Naito, M., Hayashi, S., Yoshida, H., Nishikawa, S., Shultz, L. D., and Takahashi, K. (1991). Abnormal differentiation of tissue macrophage populations in 'osteopetrosis' (op) mice defective in the production of macrophage colony-stimulating factor. Am. J. Pathol. 139, 657-667.
114. Kodama, H., Nose, M., Niida, S., and Yamasaki, A. (1991). Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med. 173, 1291-1294.
115. Kodama, H., Yamasaki, A., Nose, M., Niida, S., Ohgame, Y., Abe, M., Kumegawa, M., and Suda, T. (1991). Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J. Exp. Med. 173, 269-272.
116. Felix, R., Cecchini, M. G., and Fleisch, H. (1990). Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology (Baltimore) 127, 2592-2594.
117. Felix, R., Cecchini, M. G., Hofstetter, W., Elford, P. R., Stutzer, A., and Fleisch, H. (1990). Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J. Bone Miner. Res. 5, 781-789.
118. Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A., Jr., Ahmed-Ansari, A., Sell, K. W., Pollard, J. W., and Stanley, E. R. (1990). Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. U.S.A. 87, 4828-4832.
119. Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., and Nishikawa, S. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (London) 345, 442-444.
120. Naito, M., Umeda, S., Yamamoto, T., Moriyama, H., Umezu, H., Hasegawa, G., Usuda, H., Shultz, L. D., and Takahashi, K. (1996). Development, differentiation, and phenotypic heterogeneity of murine tissue macrophages. J. Leukocyte Biol. 59, 133-138.
121. Araki, M., Fukumatsu, Y., Katabuchi, H., Shultz, L. D., Takahashi, K., and Okamura, H. (1996). Follicular development and ovulation in macrophage colony-stimulating factor-deficient mice homozygous for the osteopetrosis (op) mutation. Biol. Reprod. 54, 478-484.
122. Pollard, J. W., and Hennighausen, L. (1994). Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc. Natl. Acad. Sci. U.S.A. 91, 9312-9316.
123. Nilsson, S. K., Lieschke, G. J., Garcia-Wijnen, C. C., Williams, B., Tzelepis, D., Hodgson, G., Grail, D., Dunn, A. R., and Bertoncello, I. (1995). Granulocyte-macrophage colony-stimulating factor is not responsible for the correction of hematopoietic deficiencies in the maturing op/op mouse. Blood 86, 66-72.
124. Lieschke, G. J., Stanley, E., Grail, D., Hodgson, G., Sinickas, V., Gall, J. A., Sinclair, R. A., and Dunn, A. R. (1994). Mice lacking both macrophage- and granulocyte-macrophage colony-stimulating factor have macrophages and coexistent osteopetrosis and severe lung disease. Blood 84, 27-35.
125. Russell, E. S. (1979). Hereditary anemias of the mouse: A review for geneticists. Adv. Genet. 20, 357-459.
126. Besmer, P. (1991). The kit ligand encoded at the murine Steel locus: A pleiotropic growth and differentiation factor. Curr. Opin. Cell Biol. 3, 939-946.
127. Torihashi, S., Ward, S. M., and Sanders, K. M. (1997). Development of c-Kit-positive cells and the onset of electrical rhythmicity in murine small intestine. Gastroenterology 112, 144-155.
128. Sanders, K. M. (1996). A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 111, 492-515.
129. Klimpel, G. R., Chopra, A. K., Langley, K. E., Wypych, J., Annable, C. A., Kaiserlian, D., Ernst, P. B., and Peterson, J. W. (1995). A role for stem cell factor and c-kit in the murine intestinal tract secretory response to cholera toxin. J. Exp. Med. 182, 1931-1942.
130. Leigh, B. R., Khan, W., Hancock, S. L., and Knox, S. J. (1995). Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation. Radiat. Res. 142, 12-15.
131. Mackarehtschian, K., Hardin, J. D., Moore, K. A., Boast, S., Goff, S. P., and Lemischka, I. R. (1995). Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3, 147-161.
132. Brown, M. A., Metcalf, D., and Gough, N. M. (1994). Leukaemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation. Cytokine 6, 300-309.
133. Hawley, R. G. (1994). Hematopathology of interleukin 6-type cytokines. Stem Cells 1, 155-171.
134. Biffl, W. L., Moore, E. E., Moore, F. A., and Peterson, V. M. (1996). Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann. Surg. 224, 647-664.
135. Akira, S., and Kishimoto, T. (1992). The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin. Cancer Biol. 3, 17-26.
136. Hirano, T., and Kishimoto, T. (1989). Interleukin 6 and plasma cell neoplasias. Prog. Growth Factor Res. 1, 133-142.
137. Gu, Z. J., Costes, V., Lu, Z. Y., Zhang, X. G., Pitard, V., Moreau, J. F., Bataille, R., Wijdenes, J., Rossi, J. F., and Klein, B. (1996). Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 88, 3972-3986.
138. Westendorf, J. J., and Jelinek, D. F. (1996). Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression. J. Immunol. 157, 3081-3088.
139. Murakami-Mori, K., Taga, T., Kishimoto, T., and Nakamura, S. (1995). AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J. Clin. Invest. 96, 1319-1327.
140. Cai, J., Gill, P. S., Masood, R., Chandrasoma, P., Jung, B., Law, R. E., and Radka, S. F. (1994). Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma. Am. J. Pathol. 145, 74-79.
141. Yoshimura, A., Ichihara, M., Kinjyo, I., Moriyama, M., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Hara, T., and Miyajima, A. (1996). Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J. 15, 1055-1063.
142. Pennica, D., Wood, W. I., and Chien, K. R. (1996). Cardiotrophin-1: A multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev. 7, 81-91.
143. Pennica, D., Arce, V., Swanson, T. A., Vejsada, R., Pollock, R. A., Armanini, M., Dudley, K., Phillips, H. S., Rosenthal, A., Kato, A. C., and Henderson, C. E. (1996). Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons. Neuron 17, 63-74.
144. Sheng, Z., Pennica, D., Wood, W. I., and Chien, K. R. (1996). Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development (Cambridge, UK) 122, 419-428.
145. Ishikawa, M., Saito, Y., Miyamoto, Y., Kuwahara, K., Ogawa, E., Nakagawa, O., Harada, M., Masuda, I., and Nakao, K. (1996). cDNA cloning of rat cardiotrophin-1 (CT-1): Augmented expression of CT-1 gene in ventricle of genetically hypertensive rats. Biochem. Biophys. Res. Commun. 219, 377-381.
146. Pennica, D., King, K. L., Shaw, K. J., Luis, E., Rullamas, J., Luoh, S. M., Darbonne, W. C., Knutzon, D. S., Yen, R., Chien, K. R., Baker, J. B., and Wood, W. I. (1995). Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 92, 1142-1146.
147. Stewart, C. L. (1994). Leukaemia inhibitory factor and the regulation of pre-implantation development of the mammalian embryo. Mol. Reprod. Dev. 39, 233-238.
148. Kobayashi, S., Teramura, M., Oshimi, K., and Mizoguchi, H. (1994). Interleukin 11. Leuk. Lymphoma 15, 45-49.
149. Quesniaux, V. F. (1994). Interleukin 11. Leuk. Lymphoma 14, 241-249.
150. Neben, S., and Turner, K. (1993). The biology of interleukin 11. Stem Cells 2, 156-162.
151. Chang, M., Williams, A., Ishizawa, L., Knoppel, A., van de Ven, C., and Cairo, M. S. (1996). Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B streptococcal sepsis in neonatal rats. Blood Cells, Mol., Dis. 22, 57-67.
152. Chang, M., Suen, Y., Meng, G., Buzby, J. S., Bussel, J., Shen, V., van de Ven, C., and Cairo, M. S. (1996). Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production. Blood 88, 3354-3362.
153. Stockli, K. A., Lottspeich, F., Sendtner, M., Masiakowski, P., Carroll, P., Gotz, R., Lindholm, D., and Thoenen, H. (1989). Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Nature (London) 342, 920-923.
154. Friedman, B., Scherer, S. S., Rudge, J. S., Helgren, M., Morrisey, D., McClain, J., Wang, D. Y., Wiegand, S. J., Furth, M. E., Lindsay, R. M., and Ip, N. Y. (1992). Regulation of ciliary neurotrophic factor expression in myelin-related Schwann cells in vivo. Neuron 9, 295-305.
155. Sendtner, M., Stockli, K. A., and Thoenen, H. (1992). Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J. Cell Biol. 118, 139-148.
156. Stockli, K. A., Lillien, L. E., Naher-Noe, M., Breitfeld, G., Hughes, R. A., Raff, M. C., Thoenen, H., and Sendtner, M. (1991). Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J. Cell Biol. 115, 447-459.
157. Kishimoto, T., Hibi, M., Murakami, M., Narazaki, M., Saito, M., and Taga, T. (1992). The molecular biology of interleukin 6 and its receptor. Ciba Found. Symp. 167, 5-16.
158. Zhang, X. G., Gu, J. J., Lu, Z. Y., Yasukawa, K., Yancopoulos, G. D., Turner, K., Shoyab, M., Taga, T., Kishimoto, T., Bataille, R., and Klein, B. (1994). Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J. Exp. Med. 179, 1337-1342.
159. Nishimoto, N., Ogata, A., Shima, Y., Tani, Y., Ogawa, H., Nakagawa, M., Sugiyama, H., Yoshizaki, K., and Kishimoto, T. (1994). Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J. Exp. Med. 179, 1343-1347.
160. Miles, S. A., Rezai, A. R., Salazar-Gonzalez, J. F., Vander Meyden, M., Stevens, R. H., Logan, D. M., Mitsuyasu, R. T., Taga, T., Hirano, T., Kishimoto, T., and Martinez-Maza, O. (1990). AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl. Acad. Sci. U.S.A. 87, 4068-4072.
161. Murakami-Mori, K., Taga, T., Kishimoto, T., and Nakamura, S. (1995). AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J. Clin. Invest. 96, 1319-1327.
162. Miles, S. A., Martinez-Maza, O., Rezai, A., Magpantay, L., Kishimoto, T., Nakamura, S., Radka, S. F., and Linsley, P. S. (1992). Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255, 1432-1434.
163. Nair, B. C., DeVico, A. L., Nakamura, S., Copeland, T. D., Chen, Y., Patel, A., O'Neil, T., Oroszlan, S., Gallo, R. C., and Sarngadharan, M. G. (1992). Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 255, 1430-1432.
164. Miyaura, C., Onozaki, K., Akiyama, Y., Taniyama, T., Hirano, T., Kishimoto, T., and Suda, T. (1988). Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (Ml). FEBS Lett. 234, 17-21.
165. Hilton, D. J., Hilton, A. A., Raicevic, A., Rakar, S., Harrison-Smith, M., Gough, N. M., Begley, C. G., Metcalf, D., Nicola, N. A., and Willson, T. A. (1994). Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J. 13, 4765-4775.
166. Hilton, D. J. (1992). LIF: Lots of interesting functions. Trends Biochem. Sci. 17, 72-76.
167. Bruce, A. G., Hoggatt, I. H., and Rose, T. M. (1992). Oncostatin M is a differentiation factor for myeloid leukemia cells. J. Immunol. 149, 1271-1275.
168. Pennica, D., Shaw, K. J., Swanson, T. A., Moore, M. W., Shelton, D. L., Zioncheck, K. A., Rosenthal, A., Taga, T., Paoni, N. F., and Wood, W. I. (1995). Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270, 10915-10922.
169. Yang, Y. C., and Yin, T. (1992). Interleukin-11 and its receptor. BioFactors 4, 15-21.
170. Bellido, T., Stahl, N., Farruggella, T. J., Borba, V., Yancopoulos, G. D., and Manolagas, S. C. (1996). Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/ osteoblastic cells. J. Clin. Invest. 97, 431-437.
171. Hui, W., Bell, M., and Carroll, G. (1996). Oncostatin M (OSM) stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 8, 495-500.
172. Shen, M. M., Skoda, R. C., Cardiff, R. D., Campos-Torres, J., Leder, P., and Ornitz, D. M. (1994). Expression of LIF in transgenic mice results in altered thymic epithelium and apparent interconversion of thymic and lymph node morphologies. EMBO J. 13, 1375-1385.
173. Koshimizu, U., Taga, T., Watanabe, M., Saito, M., Shirayoshi, Y., Kishimoto, T., and Nakatsuji, N. (1996). Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells. Development (Cambridge, UK) 122, 1235-1242.
174. Rao, M. S., Symes, A., Malik, N., Shoyab, M., Fink, J. S., and Landis, S. C. (1992). Oncostatin M regulates VIP expression in a human neuroblastoma cell line. NeuroReport 3, 865-868.
175. Sendtner, M., Carroll, P., Holtmann, B., Hughes, R. A., and Thoenen, H. (1994). Ciliary neurotrophic factor. J. Neurobiol. 25, 1436-1453.
176. Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844-2853.
177. Benigni, F., Fantuzzi, G., Sacco, S., Sironi, M., Pozzi, P., Dinarello, C. A., Sipe, J. D., Poli, V., Cappelletti, M., Paonessa, G., Pennica, D., Panayotatos, N., and Ghezzi, P. (1996). Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 87, 1851-1854.
178. Simon, R., Thier, M., Kruttgen, A., Rose-John, S., Weiergraber, O., Heinrich, P. C., Schroder, J. M., and Weis, J. (1995). Human CNTF and related cytokines: Effects on DRG neurone survival. NeuroReport 7, 153-157.
179. Pennica, D., King, K. L., Shaw, K. J., Luis, E., Rullamas, J., Luoh, S. M., Darbonne, W. C., Knutzon, D. S., Yen, R., Chien, K. R., Baker, J. B., and Wood, W. I. (1995). Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 92, 1142-1146.
180. Matsui, H., Fujio, Y., Kunisada, K., Hirota, H., and Yamauchi-Takihara, K. (1996). Leukemia inhibitory factor induces a hypertrophic response mediated by gp130 in murine cardiac myocytes. Res. Commun. Mol. Pathol. Pharmacol. 93, 149-162.
181. Wallace, P. M., MacMaster, J. F., Rillema, J. R., Peng, J., Burstein, S. A., and Shoyab, M. (1995). Thrombocytopoietic properties of oncostatin M. Blood 86, 1310-1315.
182. Berg, M., Fraker, D. L., and Alexander, H. R. (1994). Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 6, 425-432.
183. Gimble, J. M., Wanker, F., Wang, C. S., Bass, H., Wu, X., Kelly, K., Yancopoulos, G. D., and Hill, M. R. (1994). Regulation of bone marrow stromal cell differentiation by cytokines whose receptors share the gp130 protein. J. Cell. Biochem. 54, 122-133.
184. Nichols, J., Chambers, I., and Smith, A. (1994). Derivation of germline competent embryonic stem cells with a combination of interleukin-6 and soluble interleukin-6 receptor. Exp. Cell Res. 215, 237-239.
185. Piquet-Pellorce, C., Grey, L., Mereau, A., and Heath, J. K. (1994). Are LIF and related cytokines functionally equivalent? Exp. Cell Res. 213, 340-347.
186. Jay, P. R., Centrella, M., Lorenzo, J., Bruce, A. G., and Horowitz, M. C. (1996). Oncostatin-M: A new bone active cytokine that activates osteoblasts and inhibits bone resorption. Endocrinology (Baltimore) 137, 1151-1158.
187. Rose, T. M., Weiford, D. M., Gunderson, N. L., and Bruce, A. G. (1994). Oncostatin M (OSM) inhibits the differentiation of pluripotent embryonic. Cytokine 6, 48-54.
188. Goldman, S. J. (1995). Preclinical biology of interleukin 11: A multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 13, 462-471.
189. Ulich, T. R., del Castillo, J., Shin, S. S., Yin, S., Duryea, D., Tarpley, J., and Samal, B. (1995). Hematologic effects of stem cell factor (SCF) and leukemia inhibitory factor (LIF) in vivo: LIF-induced thrombocytosis in SCF-primed mice. Eur. J. Haematol. 54, 217-225.
190. Mayer, P., Geissler, K., Ward, M., and Metcalf, D. (1993). Recombinant human leukemia inhibitory factor induces acute phase proteins and raises the blood platelet counts in nonhuman primates. Blood 81, 3226-3233.
191. Wallace, P. M., MacMaster, J. F., Rillema, J. R., Peng, J., Burstein, S. A., and Shoyab, M. (1995). Thrombocytopoietic properties of oncostatin M. Blood 86, 1310-1315.
192. Laterveer, L., Zijlmans, J. M., Liehl, E., Willemze, R., and Fibbe, W. E. (1996). Accelerated platelet reconstitution following transplantation of bone marrow cells derived from IL-6-treated donor mice. Ann. Hematol. 73, 239-245.
193. Baatout, S. (1996). Interleukin-6 and megakaryocytopoiesis: An update. Ann. Hematol. 73, 157-162.
194. Zeidler, C., Kanz, L., Hurkuck, F., Rittmann, K. L., Wildfang, I., Kadoya, T., Mikayama, T., Souza, L., and Weite, K. (1992). In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood 80, 2740-2745.
195. Burstein, S. A., Downs, T., Friese, P., Lynam, S., Anderson, S., Henthorn, J., Epstein, R. B., and Savage, K. (1992). Thrombocytopoiesis in normal and sublethally irradiated dogs: Response to human interleukin-6 Blood 80, 420-428.
196. Goldman S. J. (1995). Preclinical biology of interleukin 11: A multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 13, 462-471.
197. Keith, J., Jr., Albert, L., Sonis, S. T., Pfeiffer, C. J., and Schaub, R. G. (1994). IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1, 79-89.
198. Du, X. X., and Williams, D. A. (1994). Interleukin-11: A multifunctional growth factor derived from the hematopoietic microenvironment. Blood 83, 2023-2030.
199. Du, X. X., Doerschuk, C. M., Orazi, A., and Williams, D. A. (1994). A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83, 33-37.
200. Liu, Q., Du, X. X., Schindel, D. T., Yang, Z. X., Rescorla, F. J., Williams, D. A., and Grosfeld, J. L. (1996). Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J. Pediatr. Surg. 31, 1047-1050.
201. Potten, C. S. (1996). Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Stem Cells 14, 452-459.
202. Orazi, A., Du, X., Yang, Z., Kashai, M., and Williams, D. A. (1996). Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. 75, 33-42.
203. Sonis, S., Muska, A., O'Brien, J., Van Vugt, A., Langer-Safer, P., and Keith, J. (1995). Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur. J. Cancer, Part B, Oral Oncol. 4, 261-266.
204. Potten, C. S. (1995). Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation. Int. J. Cancer 62, 356-361.
205. Booth, C., and Potten, C. S. (1995). Effects of IL-11 on the growth of intestinal epithelial cells in vitro. Cell Proliferation 28, 581-594.
206. Peterson, R. L., Bozza, M. M., and Dorner, A. J. (1996). Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation. Am. J. Pathol. 149, 895-902.
207. Ikeda, K., Iwasaki, Y., Tagaya, N., Shiojima, T., and Kinoshita, M. (1995). Neuroprotective effect of cholinergic differentiation factor/leukemia inhibitory factor on wobbler murine motor neuron disease. Muscle & Nerve 18, 1344-1347.
208. Ikeda, K., Wong, V., Holmlund, T. H., Greene, T., Cedarbaum, J. M., Lindsay, R. M., and Mitsumoto, H. (1995). Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease. Ann. Neurol. 37, 47-54.
209. Mitsumoto, H., Ikeda, K., Klinkosz, B., Cedarbaum, J. M., Wong, V., and Lindsay, R. M. (1994). Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 265, 1107-1110.
210. Thoenen, H., Hughes, R. A., and Sendtner, M. (1993). Towards a comprehensive understanding of the trophic support of motoneurons. C. R. Seances Acad. Sci., Ser. 3316, 1158-1163.
211. Richardson, P. M. (1994). Ciliary neurotrophic factor: a review. Pharmacol. Ther. 63, 187-198.
212. Lindsay, R. M. (1996). Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases. Ciba Found. Symp. 196, 39-48.
213. Ure, D. R., Campenot, R. B., and Acheson, A. (1992). Cholinergic differentiation of rat sympathetic neurons in culture: Effects of factors applied to distal neurites. Dev. Biol. 154, 388-395.
214. Donato, R., Cheema, S., Finkelstein, D., Bartlett, P., and Morrison, W. (1995). Role of leukaemia inhibitory factor (LIF) in rat peripheral nerve regeneration. Ann. Acad. Med. Singapore 24, 94-100.
215. Cheema, S. S., Richards, L. J., Murphy, M., and Bartlett, P. F. (1994). Leukaemia inhibitory factor rescues motoneurones from axotomy-induced cell death. NeuroReport 5, 989-992.
216. Metcalf, D., and Gearing, D. P. (1989). Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl. Acad. Sci. U.S.A 86, 5948-5952.
217. Metcalf, D., Nicola, N. A., and Gearing, D. P. (1990). Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76, 50-56.
218. Greenberg, A. S., Nordan, R. P., McIntosh, J., Calvo, J. C., Scow, R. O., and Jablons, D. (1992). Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: A possible role for interleukin 6 in cancer cachexia. Cancer Res. 52, 4113-4116.
219. Sakata, Y., Morimoto, A., Long, N. C., and Murakami, N. (1991). Fever and acute-phase response induced in rabbits by intravenous and intracerebroventricular injection of interleukin-6. Cytokine 3, 199-203.
220. Geiger, T., Andus, T., Klapproth, J., Hirano, T., Kishimoto, T., and Heinrich, P. C. (1988). Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur. J. Immunol. 18, 717-721.
221. Clegg, C. H., Rulffes, J. T., Wallace, P. M., and Haugen, H. S. (1996). Regulation of an extrathymic T-cell development pathway by oncostatin M. Nature (London) 384, 261-263.
222. Malik, N., Haugen, H. S., Modrell, B., Shoyab, M., and Clegg, C. H. (1995). Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol. Cell. Biol. 15, 2349-2358.
223. Anonymous (1995). A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. Clin. Neuropharmacol. 18, 515-532.
224. Anonymous (1996). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46, 1244-1249.
225. Aebischer, P., Schluep, M., Deglon, N., Joseph, J. M., Hirt, L., Heyd, B., Goddard, M., Hammang, J. P., Zurn, A. D., Kato, A. C., Regli, F., and Baetge, E. E. (1996). Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2, 696-699.
226. Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., and Kohler, G. (1994). Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (London) 368, 339-342.
227. Fattori, E., Cappelletti, M., Costa, P., Sellitto, C., Cantoni, L., Carelli, M., Faggioni, R., Fantuzzi, G., Ghezzi, P., and Poli, V. (1994). Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 180, 1243-1250.
228. Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., and Taub, R. (1996). Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379-1383.
229. Ramsay, A. J., Husband, A. J., Ramshaw, I. A., Bao, S., Matthaei, K. I., Koehler, G., and Kopf, M. (1994). The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264, 561-563.
230. Bromander, A. K., Ekman, L., Kopf, M., Nedrud, J. G., and Lycke, N. Y. (1996). IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. J. Immunol. 156, 4290-4297.
231. Kopf, M., Ramsay, A., Brombacher, F., Baumann, H., Freer, G., Galanos, C., Gutierrez-Ramos, J. C., and Kohler, G. (1995). Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann. N.Y. Acad. Sci. 762, 308-318.
232. Bernad, A., Kopf, M., Kulbacki, R., Weich, N., Koehler, G., and Gutierrez-Ramos, J. C. (1994). Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system. Immunity 1, 725-731.
233. Romani, L., Mencacci, A., Cenci, E., Spaccapelo, R., Toniatti, C., Puccetti, P., Bistoni, F., and Poli, V. (1996). Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183, 1345-1355.
234. Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., and Costantini, F. (1994). Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13, 1189-1196.
235. Stewart, C. L., Kaspar, P., Brunet, L. J., Bhatt, H., Gadi, I., Kontgen, F., and Abbondanzo, S. J. (1992). Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature (London) 359, 76-79.
236. Bhatt, H., Brunet, L. J., and Stewart, C. L. (1991). Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. Proc. Natl. Acad. Sci. U.S.A. 88, 11408-11412.
237. Rao, M. S., Sun, Y., Escary, J. L., Perreau, J., Tresser, S., Patterson, P. H., Zigmond, R. E., Brulet, P., and Landis, S. C. (1993). Leukemia inhibitory factor mediates an injury response but not a target-directed developmental transmitter switch in sympathetic neurons. Neuron 11, 1175-1185.
238. Kwon, Y. W., Abbondanzo, S. J., Stewart, C. L., and Gurney, M. E. (1995). Leukemia inhibitory factor influences the timing of programmed synapses withdrawal from neonatal muscles. J. Neurobiol. 28, 35-50.
239. Akita, S., Malkin, J., and Melmed, S. (1996). Disrupted murine leukemia inhibitory factor (LIF) gene altenuates adrenocorticotropic hormone (ACTH) secretion. Endocrinology (Baltimore) 137, 3140-3143.
240. Escary, J. L., Perreau, J., Dumenil, D., Ezine, S., and Brulet, P. (1993). Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature (London) 363, 361-364.
241. Masu, Y., Wolf, E., Holtmann, B., Sendtner, M., Brem, G., and Thoenen, H. (1993). Disruption of the CNTF gene results in motor neuron degeneration. Nature (London) 365, 27-32.
242. DeChiara, T. M., Vejsada, R., Poueymirou, W. T., Acheson, A., Suri, C., Conover, J. C., Friedman, B., McClain, J., Pan, L., Stahl, N., Ip, N. Y., Kato, A., and Yancopoulos, G. D. (1995). Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell (Cambridge, Mass.) 83, 313-322.
243. Yoshida, K., Taga, T., Saito, M., Suematsu, S., Kumanogoh, A., Tanaka, T., Fujiwara, H., Hirata, M., Yamagami, T., Nakahata, T., Hirabayashi, T., Yoneda, Y., Tanaka, K., Wang, W. Z., Mori, C., Shiota, K., Yoshida, N., and Kishimoto, T. (1996). Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U.S.A. 93, 407-411.
244. Miyajima, A., Kitamura, T., Harada, N., Yokota, T. and Arai, K. (1992). Cytokine receptors and signal transduction. Annu. Rev. Immunol. 10, 295-331.
245. Cockerill, P. N., Shannon, M. F., Bert, A. G., Ryan, G. R., and Vadas, M. A. (1993). The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. Proc. Natl. Acad. Sci. U.S.A. 90, 2466-2470.
246. Nimer, S. D., and Uchida, H. (1995). Regulation of granulocyte-macrophage colony-stimulating factor and interleukin 3 expression. Stem Cells 13, 324-335.
247. Kopf, M., Le Gros, G., Bachmann, M., Lamers, M. C., Bluethmann, H., and Kohler, G. (1993). Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature (London) 362, 245-248.
248. Akashi, M., Shaw, G., Gross, M., Saito, M., and Koeffler, H. P. (1991). Role of AUUU sequences in stabilization of granulocyte-macrophage colony-stimulating factor RNA in stimulated cells. Blood 78, 2005-2012.
249. Burgess, A. W., Camakaris, J., and Metcalf, D. (1977). Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J. Biol. Chem. 252, 1998-2003.
250. Gough, N. M., Gough, J., Metcalf, D., Kelso, A., Grail, D., Nicola, N. A., Burgess, A. W., and Dunn, A. R. (1984). Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature (London) 309, 763-767.
251. Cebon, J., Nicola, N. A., Ward, M., Gardner, I., Dempsey, P., Layton, J., Duhrsen, U., Burgess, A. W., Nice, E. C., and Morstyn, G. (1990). Granulocyte-macrophage colony-stimulating factor (rGM-CSF) from human lymphocytes: The effect of glycosylation on receptor binding and biological activity. J. Biol. Chem. 265, 4483-4491.
252. Hercus, T. R., Bagley, C. J., Cambareri, B., Dottore, M., Woodcock, J. M., Vadas, M. A., Shannon, M. F., and Lopez, A. F. (1994). Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc. Natl. Acad. Sci. U.S.A. 91, 5838-5842.
253. 250a. Shanafelt, A. B., Johnson, K. E., and Kastelein, R. A. (1991). Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. J. Biol. Chem. 266, 13804-13810.
254. Lopez, A. F., Shannon, M. F., Hercus, T., Nicola, N. A., Cambareri, B., Dottore, M., Layton, M. J., Eglinton, L., and Vadas, M. A. (1992). Residue 21 of human granulocyte-macrophage colony-stimulating factor is critical for biological activity and for high but not low affinity binding. EMBO J. 11, 909-916.
255. Steinman, R. M. (1996). Dendritic cells and immune-based therapies. Exp. Hematol. 24, 859-862.
256. Baldwin, G. C., Benveniste, E. N., Chung, G. Y., Gasson, J. C., and Golde, D. W. (1993). Identification and characterization of a high-affinity granulocyte-macrophage colony-stimulating factor receptor on primary rat oligodendrocytes. Blood 82, 3279-3282.
257. Bussolino, F., Wang, J. M., Defilippi, P., Turrini, F., Sanavio, F., Edgell, C. J., Aglietta, M., Arese, P., and Mantovani, A. (1989). Granulocyte-and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature (London) 337, 471-473.
258. Vaux, D. L., Cory, S., and Adams, J. M. (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (London) 335, 440-442.
259. Nunez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., and Korsmeyer, S. J. (1990). Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144, 3602-3610.
260. Smith, A., Metcalf, D., and Nicola, N. A. (1997). Cytoplasmic domains of the common β-chain of the GM-CSF/IL-3/IL-5 receptors that are required for inducing differentiation or clonal suppression in myeloid leukemic cell lines. EMBO J. 16, 451-464.
261. Kinoshita, T., Yokota, T., Arai, K., and Miyajima, A. (1995). Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J. 14, 266-275.
262. Stanley, E., Lieschke, G. J., Grail, D., Metcalf, D., Hodgson, G., Gall, J. A., Maher, D. W., Cebon, J., Sinickas, V., and Dunn, A. R. (1994). Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. U.S.A. 91, 5592-5596.
263. Dranoff, G., Crawford, A. D., Sadelain, M., Ream, B., Rashid, A., Bronson, R. T., Dickersin, G. R., Bachurski, C. J., Mark, E. L., Whitsett, J. A., and Mulligan, R. C. (1994). Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264, 713-716.
264. Robb, L., Drinkwater, C. C., Metcalf, D., Li, R., Kontgen, F., Nicola, N. A., and Begley, C. G. (1995). Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc. Natl. Acad. Sci. U.S.A. 92, 9565-9569.
265. Nishinakamura, R., Miyajima, A., Mee, P. J., Tybulewicz, V. L., and Murray, R. (1996). Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 88, 2458-2464.
266. Ihle, J. N., Keller, J., Henderson, L., Klein, F., and Palaszynski, E. (1982). Procedures for the purification of interleukin 3 to homogeneity. J. Immunol. 129, 2431-2436.
267. Ihle, J. N., Keller, J., Oroszlan, S., Henderson, L. E., Copeland, T. D., Fitch, F., Prystowsky, M. B., Goldwasser, E., Schrader, J. W., Palaszynski, E., Dy, M., and Lebel, B. (1983). Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J. Immunol. 131, 282-287.
268. Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844-2853.
269. Winkler, T. H., Melchers, F., and Rolink, A. G. (1995). Interleukin-3 and interleukin-7 are alternative growth factors for the same B-cell precursors in the mouse. Blood 85, 2045-2051.
270. Chervenak, R., and Altazan, J. D. (1990). In vitro maintenance of bone marrow-resident T cell precursors in cultures supplemented with exogenous IL-3. Cell. Immunol. 130, 150-159.
271. Claesson, M. H., Martinsen, L., Goutner, A., Olsson, L., and Brix-Poulsen, P. (1982). Expanded progeny cells of diffuse cytotoxic bone marrow-derived colonies. Scand. J. Immunol. 16, 499-507.
272. Postmus, P. E., Gietema, J. A., Damsma, O., Biesma, B., Limburg, P. C., Vellenga, E., and de Vries, E. G. (1992). Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: A dose-finding study. J. Clin. Oncol. 10, 1131-1140.
273. Crapper, R. M., and Schrader, J. W. (1986). Evidence for the in vivo production and release into the serum of a T-cell lymphokine, persisting-cell stimulating factor (PSF), during graft-versus-host reactions. Immunology 57, 553-558.
274. Milburn, M. V., Hassell, A. M., Lambert, M. H., Jordan, S. R., Proudfoot, A. E., Graber, P., and Wells, T. N. (1993). A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature (London) 363, 172-176.
275. Graber, P., Proudfoot, A. E., Talabot, F., Bernard, A., McKinnon, M., Banks, M., Fattah, D., Solari, R., Peitsch, M. C., and Wells, T. N. (1995). Identification of key charged residues of human interleukin-5 in receptor binding and cellular activation. J. Biol. Chem. 270, 15762-15769.
276. Li, J., Cook, R., and Chaiken, I. (1996). Mutants of single chain interleukin 5 show asymmetric recruitment of receptor alpha and beta subunits. J. Biol. Chem. 271, 31729-31734.
277. Sanderson, C. J., Campbell, H. D., and Young, I. G. (1988). Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells. Immunol. Rev. 102, 29-50.
278. Alderson, M. R., Pike, B. L., Harada, N., Tominaga, A., Takatsu, K., and Nossal, G. J. (1987). Recombinant T cell replacing factor (interleukin 5) acts with antigen to promote the growth and differentiation of single hapten-specific B. J. Immunol. 139, 2656-2660.
279. Bertolini, J. N., Sanderson, C. J., and Benson, E. M. (1993). Human interleukin-5 induces staphylococcal A Cowan 1 strain-activated human B cells to secrete IgM. Eur. J. Immunol. 23, 398-402.
280. Clutterbuck, E., Shields, J. G., Gordon, J., Smith, S. H., Boyd, A., Callard, R. E., Campbell, H. D., Young, I. G., and Sanderson, C. J. (1987). Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur. J. Immunol. 17, 1743-1750.
281. Bischoff, S. C., Brunner, T., De Weck, A. L., and Dahinden, C. A. (1990). Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J. Exp. Med. 172, 1577-1582.
282. Akutsu, I., Kojima, T., Kariyone, A., Fukuda, T., Makino, S., and Takatsu, K. (1995). Antibody against interleukin-5 prevents antigen-induced eosinophil infiltration and bronchial hyperreactivity in the guinea pig airways. Immunol. Lett. 45, 109-116.
283. Kopf, M., Le Gros, G., Coyle, A. J., Kosco-Vilbois, M., and Brombacher, F. (1995). Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol. Rev. 148, 45-69.
284. Lefort, J., Bachelet, C. M., Leduc, D., and Vargaftig, B. B. (1996). Effect of antigen provocation of IL-5 transgenic mice on eosinophil mobilization and bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 97, 788-799.
285. Nishinakamura, R., Nakayama, N., Hirabayashi, Y., Inoue, T., Aud, D., McNeil, T., Azuma, S., Yoshida, S., Toyoda, Y., Arai, K., Miyajima, A., and Murray, R. (1995). Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 2, 211-222.
286. Nicola, N. A., Robb, L., Metcalf, D., Cary, D., Drinkwater, C. C., and Begley, C. G. (1996). Functional inactivation in mice of the gene for the interleukin-3 (IL-3)-specific receptor beta-chain: Implications for IL-3 function and the mechanism of receptor transmodulation in hematopoietic cells. Blood 87, 2665-2674.
287. Isaacs, A., and Lindenmann, J. (1957). Virus interference. 1. The interferon. Proc. R. Soc. London, Ser. B 147, 258-267.
288. Taniguchi, T., Harada, H., and Lamphier, M. (1995). Regulation of the interferon system and cell growth by the IRF transcription factors. J. Cancer Res. Clin. Oncol. 121, 516-520.
289. Stern, A. S., Magram, J., and Presky, D. H. (1996). Interleukin-12 an integral cytokine in the immune response. Life Sci. 58, 639-654.
290. Trinchieri, G., and Gerosa, F. (1996). Immunoregulation by interleukin-12. J. Leukocyte Biol. 59, 505-511.
291. Trinchieri, G. (1995). Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251-276.
292. Jacobs, B. L., and Langland, J. O. (1996). When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology 219, 339-349.
293. Landolfo, S., Gribaudo, G., Angeretti, A., and Gariglio, M. (1995). Mechanisms of viral inhibition by interferons. Therapie 65(3), 415-442.
294. Zinkernagel, R. M., and Doherty, P. C. (1974). Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (London) 248, 701-702.
295. Billiau, A. (1996). Interferon-gamma: Biology and role in pathogenesis. Adv. Immunol. 62, 61-130.
296. Farrar, M. A., and Schreiber, R. D. (1993). The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11, 571-611.
297. Hwang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms, M. J., Hamilton, J. A., Whitty, G., Bertoncello, I., and Kola, I. (1995). A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl. Acad. Sci. U.S.A. 92, 11284-11288.
298. Durbin, J. E., Hackenmiller, R., Simon, M. C., and Levy, D. E. (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell (Cambridge, Mass.) 84, 443-450.
299. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., Carver-Moore, K., DuBois, R. N., Clark, R., Aguet, M., and Schreiber, R. D. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (Cambridge, Mass.) 84, 431-442.
300. Gazzinelli, R. T., Wysocka, M., Hieny, S., Scharton-Kersten, T., Cheever, A., Kuhn, R., Muller, W., Trinchieri, G., and Sher, A. (1996). In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 157, 798-805.
301. Ho, A. S., and Moore, K. W. (1994). Interleukin-10 and its receptor. Ther. Immunol. 1, 173-185.
302. de Vries, J. E. (1995). Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann. Med. 27, 537-541.
303. Banchereau, J., Briere, F., Liu, Y. J., and Rousset, F. (1994). Molecular control of B lymphocyte growth and differentiation. Stem Cells 12, 278-288.
304. D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., and Trinchieri, G. (1993). Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178, 1041-1048.
305. Biron, C. A., and Gazzinelli, R. T. (1995). Effects of IL-12 on immune responses to microbial infections: A key mediator in regulating disease outcome. Curr. Opin. Immunol. 7, 485-496.
306. Gazzinelli, R. T. (1996). Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases. Mol. Med. Today 2(6), 258-267.
307. Brunda, M. J., Luistro, L., Rumennik, L., Wright, R. B., Dvorozniak, M., Aglione, A., Wigginton, J. M., Wiltrout, R. H., Hendrzak, J. A., and Palleroni, A. V. (1996). Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol. 38, S16-S21.
308. Mattner, F., Magram, J., Ferrante, J., Launois, P., Di Padova, K., Behin, R., Gately, M. K., Louis, J. A., and Alber, G. (1996). Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26, 1553-1559.
309. Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A., Doherty, P. C., Grosveld, G. C., and Ihle, J. N. (1996). Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature (London) 382, 171-174.
310. Kaplan, M. H., Sun, Y. L., Hoey, T., and Grusby, M. J. (1996). Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature (London) 382, 174-177.
311. Seder, R. A., and Paul, W. E. (1994). Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12, 635-673.
312. Smith, K. A. (1980). T-cell growth factor. Immunol. Rev. 51, 337-357.
313. Wingren, A. G., Parra, E., Varga, M., Kalland, T., Sjögren, H. O., Hedlund, G., and Dohlsten, M. (1995). T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol. 15, 235-253.
314. Renauld, J. C., Kermouni, A., Vink, A., Louahed, J., and Van Snick, J. (1995). Interleukin-9 and its receptor: Involvement in mast cell differentiation and T cell oncogenesis. J. Leukocyte Biol. 57, 353-360.
315. Zurawski, G., and de Vries, J. E. (1994). Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 15, 19-26.
316. Fitch, F. W., Stack, R., Fields, P., Lancki, D. W., and Cronin, D. C. (1995). Regulation of T lymphocyte subsets. Ciba Found. Symp. 195, 68-80.
317. Schmitt, E., Germann, T., Goedert, S., Hoehn, P., Huels, C., Koelsch, S., Kuhn, R., Muller, W., Palm, N., and Rude, E. (1994). IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J. Immunol. 153, 3989-3996.
318. Locksley, R. M., Wakil, A. E., Corry, D. B., Pingel, S., Bix, M., and Fowell, D. J. (1995). The development of effector T cell subsets in murine Leishmania major infection. Ciba Found. Symp. 195, 110-117.
319. Reiner, S. L., and Locksley, R. M. (1995). The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13, 151-177.
320. Sakata, T., Iwagami, S., Tsuruta, Y., Teraoka, H., Tatsumi, Y., Kita, Y., Nishikawa, S., Takai, Y., and Fujiwara, H. (1990). Constitutive expression of interleukin-7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line. J Leukocyte Biol. 48, 205-212.
321. Tagaya, Y., Bamford, R. N., DeFilippis, A. P., and Waldmann, T. A. (1996). IL-15: A pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 4, 329-336.
322. Cosman, D., Kumaki, S., Ahdieh, M., Eisenman, J., Grabstein, K. H., Paxton, R., DuBose, R., Friend, D., Park, L. S., Anderson, D., and Giri, J. G. (1995). Interleukin 15 and its receptor. Ciba Found. Symp. 195, 221-229.
323. Kirman, I., and Nielsen, O. H. (1996). Increased numbers of interleukin-15-expressing cells in active ulcerative colitis. Am. J. Gastroenterol. 91, 1789-1794.
324. Rebollo A., Gomez J., and Martinez, A. C. (1996). Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Adv. Immunol. 63, 127-196.
325. Smith, K. A. (1992). Interleukin-2. Curr. Opin. Immunol. 4, 271-276.
326. Smith, K. A. (1980). T-cell growth factor. Immunol. Rev. 51, 337-357.
327. Renauld, J. C., Kermouni, A., Vink, A., Louahed, J., and Van Snick, J. (1995). Interleukin-9 and its receptor: Involvement in mast cell differentiation and T cell oncogenesis. J. Leukocyte Biol. 57, 353-360.
328. de Waal Malefyt, R., Figdor, C. G., and de Vries, J. E. (1993). Effects of interleukin 4 on monocyte functions: Comparison to interleukin 13. Res. Immunol. 144, 629-633.
329. Banchereau, J., Bidaud, C., Fluckiger, A. C., Galibert, L., Garrone, P., Malisan, F., and Pandrau, D. (1993). Effects of interleukin 4 on human B-cell growth and differentiation. Res. Immunol. 144, 601-605.
330. Rebollo, A., Gomez, J., and Martinez-A, C. (1996). Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4. Adv. Immunol. 63, 127-196.
331. Zurawski, G., and de Vries, J. E. (1994). Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 12, 169-174.
332. Zurawski, G., and de Vries, J. E. (1994). Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today 15, 19-26.
333. Zlotnik, A., and Moore, T. A. (1995). Cytokine production and requirements during T-cell development. Curr. Opin. Immunol. 7, 206-213.
334. von Rohr, A., and Thatcher, N. (1992). Clinical applications of interleukin-2. Prog. Growth Factor Res. 4, 229-246.
335. Smith, K. A. (1992). Interleukin-2. Curr. Opin. Immunol. 4, 271-276.
336. Sondel, P. M., Hank, J. A., Kohler, P. C., Sosman, J. A., Weil-Hillman, G., and Fisch, P. (1989). The cellular immunotherapy of cancer: Current and potential uses of interleukin-2. Crit. Rev. Oncol. Hematol. 9, 125-147.
337. Sznol, M., and Parkinson, D. R. (1994). Clinical applications of IL-2. Oncology 8, 61-67.
338. Reisser, D., Pinard, D., and Jeannin, J. F. (1996). IL-13 restores an in vitro specific cytolytic response of spleen cells from tumor-bearing rats. J. Leukocyte Biol. 59, 728-732.
339. Tepper, R. I., Pattengale, P. K., and Leder, P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell (Cambridge, Mass.) 57, 503-512.
340. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., De Coene, C., Selz, F., Le Deist, F., and Fischer, A. (1996). Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency XI bone marrow cells. Blood 88, 3901-3909.
341. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994). Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403.
342. Komschlies, K. L., Gregorio, T. A., Gruys, M. E., Back, T. C., Faltynek, C. R., and Wiltrout, R. H. (1994). Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J. Immunol. 152, 5776-5784.
343. Tepper, R. I., and Mule, J. J. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5, 153-164.
344. Lynch, D. H., and Miller, R. E. (1994). Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J. Exp. Med. 179, 31-42.
345. Miller, A. R., McBride, W. H., Dubinett, S. M., Dougherty, G. J., Thacker, J. D., Shau, H., Kohn, D. B., Moen, R. C., Walker, M. J., Chin, R., Schuck, B. L, Rosenblatt, J. A., Huang, M., Dhanani, S., Rhoades, K., and Economou, J. S. (1993). Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: Comparison of immunologic properties with interleukin-2. Blood 82, 3686-3694.
346. Kinter, A., and Fauci, A. S. (1996). Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement. Immunol. Res. 15, 1-15.
347. Renauld, J. C., van der Lugt, N., Vink, A., van Roon, M., Godfraind, C., Warnier, G., Merz, H., Feller, A., Berns, A., and Van Snick, J. (1994). Thymic lymphomas in interleukin 9 transgenic mice. Oncogenee 9, 1327-1332.
348. Finkelman, F. D., Holmes, J., Katona, I. M., Urban, J., Jr., Beckmann, M. P., Park, L. S., Schooley, K. A., Coffman, R. L., Mosmann, T. R., and Paul, W. E. (1990). Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8, 303-333.
349. Chatelain, R., Varkila, K., and Coffman, R. L. (1992). IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148, 1182-1187.
350. Lai, Y. H., Heslan, J. M., Poppema, S., Elliot, J. F., and Mosmann, T. R. (1996). Continuous administration of 11-13 to mice induces extramedullary hemopoiesis and monocytosis. J. Immunol. 156, 3166-3173.
351. Boerman, O. C., Gregorio, T. A., Grzegorzewski, K. J., Faltynek, C. R., Kenny, J. J., Wiltrout, R. H., and Komschlies, K. L. (1995). Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants. J. Leukocyte Biol. 58, 151-158.
352. Valenzona, H. O., Pointer, R., Ceredig, R., and Osmond, D. G. (1996). Prelymphomatous B cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: Precursor B cell dynamics, microenvironmental organization and osteolysis. Exp. Hematol. 24, 1521-1529.
353. Mertsching, E., Grawunder, U., Meyer, V., Rolink, T., and Ceredig, R. (1996). Phenotypic and functional analysis of B lymphopoiesis in interleukin-7-transgenic mice: Expansion of pro/pre-B cell number and persistence of B lymphocyte development in lymph nodes and spleen. Eur. J. Immunol. 26, 28-33.
354. Fisher, A. G., Burdet, C., Bunce, C., Merkenschlager, M., and Ceredig, R. (1995). Lymphoproliferative disorders in IL-7 transgenic mice: Expansion of immature B cells which retain macrophage potential. Int. Immunol. 7, 415-423.
355. Mertsching, E., Burdet, C., and Ceredig, R. (1995). IL-7 transgenic mice: Analysis of the role of IL-7 in the differentiation of thymocytes in vivo and in vitro. Int. Immunol. 7, 401-414.
356. Rich, B. E., and Leder, P. (1995). Transgenic expression of interleukin 7 restores T cell populations in nude mice. J. Exp. Med. 181, 1223-1228.
357. Rich, B. E., Campos-Torres, J., Tepper, R. I., Moreadith, R. W., and Leder, P. (1993). Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J. Exp. Med. 177, 305-316.
358. Uehira, M., Matsuda, H., Hikita, I., Sakata, T., Fujiwara, H., and Nishimoto, H. (1993). The development of dermatitis infiltrated by gamma delta T cells in IL-7 transgenic mice. Int. Immunol. 5, 1619-1627.
359. Fisher, A. G., Burdet, C., LeMeur, M., Haasner, D., Gerber, P., and Ceredig, R. (1993). Lymphoproliferative disorders in an IL-7 transgenic mouse line. Leukemia 7, S66-S68.
360. Fraser, C. C., Thacker, J. D., Hogge, D. E., Fatur-Saunders, D., Takei, F., and Humphries, R. K. (1993). Alterations in lymphopoiesis after hematopoietic reconstitution with IL-7 virus-infected bone marrow. J. Immunol. 151, 2409-2418.
361. Abdul-Hai, A., Or, R., Slavin, S., Friedman, G., Weiss, L., Matsa, D., and Ben-Yehuda, A. (1996). Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice. Exp. Hematol. 24, 1416-1422.
362. Bolotin, E., Smogorzewska, M., Smith, S., Widmer, M., and Weinberg, K. (1996). Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 88, 1887-1894.
363. Horak, I., Lohler, J., Ma, A., and Smith, K. A. (1995). Interleukin-2 deficient mice: A new model to study autoimmunity and self-tolerance. Immunol. Rev. 148, 35-44.
364. Ma, A., Datta, M., Margosian, E., Chen, J., and Horak, I. (1995). T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J. Exp. Med. 182, 1567-1572.
365. Kundig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkernagel, R. M., and Horak, I. (1993). Immune responses in interleukin-2-deficient mice. Science 262, 1059-1061.
366. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C., and Horak, I. (1993). Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell (Cambridge, Mass.) 75, 253-261.
367. Kramer, S., Schimpl, A., and Hunig, T. (1995). Immunopathology of interleukin (IL) 2-deficient mice: Thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J. Exp. Med. 182, 1769-1776.
368. Ma, A., Datta, M., Margosian, E., Chen, J., and Horak, I. (1995). T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J. Exp. Med. 182, 1567-1572.
369. Finkelman, F. D., Katona, I. M., Urban, J., Jr., Holmes, J., Ohara, J., Tung, A. S., Sample, J. V., and Paul, W. E. (1988). IL-4 is required to generate and sustain in vivo IgE responses. J. Immunol. 141, 2335-2341.
370. Sadick, M. D., Heinzel, F. P., Holaday, B. J., Pu, R. T., Dawkins, R. S., and Locksley, R. M. (1990). Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171, 115-127.
371. Bhatia, S. K., Tygrett, L. T., Grabstein, K. H., and Waldschmidt, T. J. (1995). The effect of in vivo IL-7 deprivation on T cell maturation. J. Exp. Med. 181, 1399-1409.
372. Grabstein, K. H., Waldschmidt, T. J., Finkelman, F. D., Hess, B. W., Alpert, A. R., Boiani, N. E., Namen, A. E., and Morrissey, P. J. (1993). Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp. Med. 178, 257-264.
373. von Freeden-Jeffry, U., Vieira, P., Lucian, L. A., McNeil, T., Burdach, S. E., and Murray, R. (1995). Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181, 1519-1526.